Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s ...

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

They are so effective, in one trial, patients who took the highest dose of Wegovy, which is only prescribed for weight loss, ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

(AP Photo/Manuel Balce Ceneta) WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.